4Martin DK, Pater JL, Singer PA. Priority-setting deci- sions for new cancer drugs: a qualitative case study[J]. Lancet, 2001, 358(9294): 1676-81.
5Le Pen C, Priol G, Lilliu H. What criteria for pharma- ceuticals reimbursement? An empirical analysis of the evaluation of "medical service rendered" by reim- bursable drugs in France [J]. Eur J Health Econ, 2003, 4(1): 30-6.
6Vuorenkoski L, Toiviainen H, Hemminki E. Drug reim- bursement in Finland--a ease of explicit prioritising in special categories[J]. Health Policy, 2003, 66(2): 169-77.
7Martin DK, Hollenberg D, MaeRae S, et al. Priority setting in a hospital drug formulary: a qualitative ease study and evaluation [J]. Health Policy, 2003, 66(3): 295-303.
8Jenkings KN, Barber N. What constitutes evidence in hospital new drug decision making [J]. Soc Sci Med, 2004, 58(9): 1757-66.
9West R, Borden EK, Collet JP, et al. "Cost-effective- ness" estimates result in flawed decision-making inlisting drugs for reimbursement[J]. Can J Public Health, 2002, 93(6): 421-5.
10Kloeg PH, Steenhoek A. Calciumantagonisten: een preparaat keuze volgens de SOJA method [J]. Pharm Weekbl, 1992, 127: 1250-61.
